Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber and Mass General

Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber and Mass General

News

On December 9, 2015, Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital for technology to be utilized in Neon Therapeutics' pipeline.

Neon Therapeutics was represented by WilmerHale in this transaction, with Partners Richard Hoffman and Michael Bevilacqua, and Associate Ritu Gupta.

View Neon Therapeutics' press release for more information.